🚀 We’re thrilled to support Newronika S.p.A. in its €13.6M Series B round, fueling the future of adaptive neuromodulation. Their groundbreaking technology is set to change the game for people living with neurological disorders. Huge congrats to the Newronika team and our fellow investors for this milestone! 🎉 #Innovation #MedTech #Neuromodulation #VentureCapital #Newronika #Innogest
🚀 A Major Milestone for Newronika: €13.6M Series B Financing Secured We are proud to announce the successful closing of our €13.6 million Series B funding round, led by Fondazione ENEA Tech e Biomedical, with participation from Indaco Venture Partners SGR, Innogest Capital SGR, Wille Finance, TNBT Capital, and F3F. This funding will accelerate the development and commercialization of our AlphaDBS system, the world’s most advanced adaptive deep brain stimulation (aDBS) technology, designed to transform the treatment of Parkinson’s disease and other neurological disorders. Unlike conventional DBS, AlphaDBS dynamically adjusts stimulation in real time, optimizing therapy for each patient based on their brain signals. With Parkinson’s disease affecting over 8.5 million people worldwide, this investment brings us closer to making a tangible difference in patients’ lives by delivering next-generation, data-driven therapy that improves outcomes and quality of life. 🌍 A huge thank you to our investors and partners for believing in our vision of transforming neuromodulation. We are just getting started! 🔗 Read the full press release below #Newronika #SeriesB #AdaptiveDBS #AlphaDBS #Neuromodulation #ParkinsonsDisease #MedicalInnovation #Neurotechnology